Praluent Safety Study Requirements: A Backdoor To Ensuring Outcomes Trial Completion?
Agency requires three post-marketing studies under the FDA Amendments Act's drug safety authorities; Sanofi says some of the requirements will be answered by data collected in the ongoing ODYSSEY OUTCOMES trial.
You may also be interested in...
Advisory committee sent a clear message that pre-exposure prophylaxis studies are needed in cisgender women, but what those studies might look like, and whether the agency can exercise its statutory authorities to ensure they are conducted, is less clear.
The four-hour virtual public meeting featured "incompatible" views of the FDA and sponsor on the OCEAN data, not to mention signs of impatience and resentment, with each side criticizing the positions of the other over the safety and efficacy of the multiple myeloma drug.
With two weeks to go before hearing on whether the preterm birth prevention drug can stay on the market or be withdrawn, the lack of clarity on who will make the ultimate decision may stem from the lengthy duration of the dispute and multiple transitions within FDA’s senior leadership.